Crossmark

The Lived Experience of Patients Diagnosed with Vitiligo and a Preliminary Conceptual Disease Model: Insights from Patients, Patient Advocates, and Clinicians

Crossref DOI link: https://doi.org/10.1007/s13555-025-01510-2

Published Online: 2025-08-15

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ezzedine, Khaled https://orcid.org/0000-0002-5468-4589
Soliman, Ahmed M.

Ladd, Mary Kathleen

Patterson, Stavonnie

Sen, Rohini

Ofori, Sarah

Coyne, Karin S.

Pokrzywinski, Robin
Funding

Funding for this research was provided by:

AbbVie
License Information

Text and Data Mining valid from 2025-08-15

Version of Record valid from 2025-08-15
More Information

Article History

Received: 10 June 2025

Accepted: 29 July 2025

First Online: 15 August 2025

Declarations

:

: Khaled Ezzedine has served as a consultant for AbbVie, Lilly, Almirall, Incyte Corporation, Pfizer, Pierre Fabre Pharmaceuticals, BMS, and MSD. Ahmed M. Soliman, Stavonnie Patterson, and Rohini Sen are full-time employees of AbbVie and may hold AbbVie stock, stock options and/or patents. Mary Kathleen Ladd, Karin S. Coyne, and Robin Pokrzywinski are employees of Evidera and may hold ThermoFisher Scientific, the parent company, stock and/or stock options. Sarah Ofori was formerly employed by AbbVie and has no current financial interest in AbbVie.

: The study was conducted in accordance with the Declaration of Helsinki, and the protocol for the qualitative interviews with study patients was approved by the central institutional review board (Advarra, Inc. IRB). All transcripts were de-identified by removing all protected health information.

Document is current

Any future updates will be listed below